CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Nuvation Bio Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Nuvation Bio Inc
357 Tehama Street
Floor 3
Phone: (415) 754-3517p:415 754-3517 San Francisco, CA  94103  United States Ticker: NUVBNUVB
Business Summary
Nuvation Bio Inc. is a global biopharmaceutical company. The Company is engaged in tackling the unmet needs in oncology by developing differentiated and therapeutic candidates. Its programs include taletrectinib (ROS1 inhibitor), safusidenib (mIDH1 inhibitor), NUV-1511 (drug-drug conjugate), and NUV-868 (BET inhibitor). The Company's Taletrectinib is an oral, potent, central nervous system-active, selective, ROS1 inhibitor specifically designed for the treatment of patients with ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC). Safusidenib is a novel, oral, potent, brain penetrant, targeted inhibitor of mutant mutant isocitrate dehydrogenase 1(mIDH1). NUV-1511, a clinical-stage drug-drug conjugate (DDC), fuses a targeting agent to a widely used chemotherapy agent. Its NUV-868 is a BD2-selective, oral, small molecule bromodomain and extra-terminal (BET) inhibitor that inhibits BRD4.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202412/31/2024YesYes--Yes

Industries
SIC Code Description
8731 Commercial physical and biological research
6770 Blank checks

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, President, Chief Executive Officer, Founder David T.Hung 67 4/1/2018 4/1/2018
Chief Financial Officer and Principal Financial Officer PhilippeSauvage 48 10/7/2024 10/7/2024
Chief People Officer StacyMarkel 60 1/1/2022 10/1/2019
11 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
AnHeart Therapeutics Inc. 777 Third Avenue New York NY United States

Business Names
Business Name
AnBio Therapeutics (HK) Ltd.
AnHeart Therapeutics (Hangzhou) Co., Ltd.
AnHeart Therapeutics Inc.
11 additional Business Names available in full report.

General Information
Number of Employees: 220 (As of 12/31/2024)
Outstanding Shares: 339,668,551 (As of 3/25/2025)
Shareholders: 55
Stock Exchange: NYSE
Federal Tax Id: 850862255
Fax Number: (302) 636-5454


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, April 26, 2025